|
M
ental
I llness
C oncerns
A ll
| The new experimental drug stops the build-up of a protein called amyloid, which many scientists accept is a major cause of the disease.
The professor said the drug could significantly prevent Alzheimer's developing or delay its onset for many years.
Early clinical testing has confirmed 'PBT2' is fast-acting.
Levels of amyloid dropped by 60 per cent within 24 hours of a single dose.!!!
It also found it suppressed the impairment of memory function.
More human studies begin in Sweden next month followed by a major international trial.
back to index page
|